Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
about
Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyThe dual role of tumor lymphatic vessels in dissemination of metastases and immune response developmentMatrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-FluorouracilA novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsPhase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeGenetic polymorphism in a VEGF-independent angiogenesis gene ANGPT1 and overall survival of colorectal cancer patients after surgical resectionAntibody-based therapeutics to watch in 2011.A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.Efficacy of Tie2 receptor antagonism in angiosarcomaA Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on SurvivalAMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.Major clinical research advances in gynecologic cancer in 2012.A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.Expression of angiopoietin-TIE system components in angiosarcomaElevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding.Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases.AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.Novel targets for VEGF-independent anti-angiogenic drugs.Overcoming resistance to antiangiogenic therapies.Monoclonal antibodies therapies for ovarian cancer.Targeting angiopoietin-2 signaling in cancer therapy.Targeting angiogenesis in renal cell carcinoma.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Novel therapies, including enzastaurin, in the treatment of ovarian cancer.An overview of early investigational therapies for chemoresistant ovarian cancer.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis.Tumor angiogenesis revisited: Regulators and clinical implications.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method.Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
P2860
Q26991997-8A42FA63-02D3-4C51-B102-6B965523067AQ26993238-64E1129A-B887-4B29-B5AA-B580C7DE9FCEQ28076945-9EE06603-7EBB-490A-B2D8-C9BCCA6C618CQ28478505-50CCD941-0DCD-493A-8776-1EB2FBA1D7BAQ31110832-D0B1EC79-E826-49AA-842A-0A330C54E017Q33424270-761BF0A0-411A-4D93-ADB2-C2AF2078B66AQ33898877-6E0696D6-F51E-446C-AFA2-BAB3F7E5D4ADQ33996024-333276BA-E33D-4713-A372-DF6EEE9AD621Q34056295-7B0EC711-6732-49E2-9EE7-98A3420BA4BAQ34230336-25F9E8AB-1F11-406A-9770-510DA6942F77Q34570079-7FD82CA3-BD74-49DC-A7FF-BD56AE39106AQ34956830-1B493518-7E33-45B7-BD73-39D49C05319FQ35536088-93378D90-2585-4D56-B91B-ADD997CA2FEBQ35544474-E7CCE3B2-D337-4771-A0A5-7C97955F103AQ35813114-2FE2F5CD-8C29-488A-8334-894F5D0A7D28Q35836039-75BAEBA5-DD3F-4CC0-8274-983E752048F9Q36172919-38ED3C69-16BE-4AB7-9BF7-00D457BE0D3AQ36338069-2343E07C-7374-4A3D-BE42-FED58F4ED3F6Q36480124-572474D3-B786-426B-9A3F-425CA8B9440FQ36503472-450498FB-DE9D-4917-819D-A9CAB865B434Q36547047-BC397047-EF08-416E-A9BF-1053758A289EQ36671874-53793998-5CAC-471A-8EE9-D886309DCE35Q36997066-C8DBE4F7-B346-482A-9035-DFB1B0F838BEQ37088633-BF2884A6-0FED-4789-8D4A-A1D36ED30947Q37507440-5ABE57B7-A08D-45D3-A7E2-444EB1CF9963Q37826430-C8FEBC9C-AB98-4D8B-8BED-067F5C72BFA4Q37984612-7FABA911-4E47-4F24-878C-F829A59B7F9EQ38024765-67245D16-5582-46C2-9539-A08C5BAE93EAQ38078400-EB159A2E-5DF4-460D-AE5B-F6E81C4BCC02Q38101997-6E7C10CE-D25A-4A73-A3C5-425038C92288Q38132231-9AC78A52-A8DB-496A-8BC1-330ED9ABADF0Q38184622-6533C2A5-343C-49C1-AE49-265A984874B2Q38198095-87EF8AF0-A6FC-4254-ADE0-D6608C9FD913Q38553247-5FAEE74A-892A-4709-B2F0-4B7D57DD1741Q38757677-A5FC292B-1550-4948-9F9C-544780AA7C52Q39302290-31B9CF81-653B-43EC-A8F7-FA9CE4CBC6CCQ39393740-6C3AD786-2788-4818-891A-17F22F8A1E54Q39403862-3500494F-7189-450E-B66B-CEEA613D788DQ42466000-BE277B91-E947-443D-BBF5-30175EA380EBQ43471758-E89006A0-D982-4B65-A915-092459FD989F
P2860
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Phase 1 study of AMG 386, a se ...... ts with advanced solid tumors.
@en
Phase 1 study of AMG 386, a se ...... ts with advanced solid tumors.
@nl
type
label
Phase 1 study of AMG 386, a se ...... ts with advanced solid tumors.
@en
Phase 1 study of AMG 386, a se ...... ts with advanced solid tumors.
@nl
prefLabel
Phase 1 study of AMG 386, a se ...... ts with advanced solid tumors.
@en
Phase 1 study of AMG 386, a se ...... ts with advanced solid tumors.
@nl
P2093
P1476
Phase 1 study of AMG 386, a se ...... ts with advanced solid tumors.
@en
P2093
Alain C Mita
Anthony Tolcher
Chris H Takimoto
Erik Rasmussen
John Sarantopoulos
Kamalesh Sankhala
Leslie Wood
Manuel Valdivieso
Michael B Bass
Monica Mita
P304
P356
10.1158/1078-0432.CCR-09-3368
P407
P577
2010-05-25T00:00:00Z